The market for DPRR-4 inhibitor class diabetes treatment, valued at KRW 600 billion annually, is undergoing a significant shift. Following the expiration of substance patents for major original products, generics have been launched, rapidly expanding their prescriptions. At the same time, the growth of original products is experiencing a slowdown.

The prescription sales of Tenelia (teneligliptin) generics have increased by 83% year-over-year (YoY), resulting in a widening gap between the generics and the originals. The sales of Galvus (vildagliptin) generics will soon surpass those of the original product. Moreover, Januvia (sitagliptin) generics have rapidly expanded their market impact since S